Navigation Links
Precyse Executive Authors New Book, The Legal Health Record
Date:10/1/2007

Precyse Solutions' Cheryl Servais, MPH, RHIA, VP of Compliance and Privacy Officer, new book summarizes current standards for a legal health record

WAYNE, Pa., Oct. 1 /PRNewswire/ -- Precyse Solutions, the leader in driving peak performance within Health Information Management (HIM) departments, today announced that its Vice President of Compliance and Privacy Officer, Cheryl Servais, MPH, RHIA, authored The Legal Health Record. With more than 30 years of progressive experience in the healthcare industry, Servais provides expert insight on the most recent changes in what constitutes a legal health record. The Legal Health Record describes how the legal process applies to electronic health records (EHRs) and provides an in-depth discussion on how to establish and maintain the legal EHR.

"The Legal Health Record serves as an informative resource for HIM professionals and health law attorneys, who need to be aware of the legal changes surrounding health records, especially electronic health records (EHRs)," said Servais. "The book provides useful information on how to responsibly manage EHRs and comply with legal regulations."

"Precyse colleagues are thought leaders in their profession and we are thrilled to announce the latest success of one of our team members," said Rob Healy, President, Precyse Solutions. "At Precyse, we are committed to the HIM industry, and Cheryl epitomizes our definition of an experienced professional dedicated to improving HIM department performance. Cheryl's work in the HIM industry is highly regarded and admired, and we congratulate her on adding this informative and practical book to her already extensive list of HIM thought leadership accomplishments."

HIM professionals and health law attorneys will utilize The Legal Health Record to gain insight into many key areas, including: the electronic health record as a business record; how rules of evidence apply to health records; the new Electronic Discovery rule a
'/>"/>

SOURCE Precyse Solutions
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Where Burnt Out Executives De-stress in Natures Lap
2. Asian Business Executives Urged to Be Eco-friendly
3. BMA Welcomes Scottish Executives Move to Raise the Purchase Age of Cigarettes
4. Dr. Scott Hammer Authors Two New Guidelines for HIV Treatment
5. Authors Review Astrodome Medical Response to Hurricane Katrina
6. Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn
7. FDA considers nicotine lollipops illegal
8. Morality More Effective Than Legality In Preventing Drug Abuse
9. Forensic Phonetics – Scientific Solution for Legal Problem
10. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
11. Illegal Drug Use In England Mounting Up At An Alarming Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... A Florida State University College of Medicine re... important new layer of regulation in the cell div...anding of the way cancer begins. , Wang, an assi...ege of Medicine, said the findings will lead to an...d to the design of new drugs that kill cancer cell...
(Date:11/21/2008)...PRNewswire-FirstCall/ -- The Providence Service,C...Craig A. Norris, the Company,s,Chief Operating Of...f,Directors. Mr. Norris, appointment fills the v...en I. Geringer and returns the board to six member... the Board. , Mr. Norris, age 41, has been ...
(Date:11/21/2008)...ad to a novel technique to combat cancer, study sa...ws) -- Belgian researchers have discovered that so...or food, and this might lead to new treatments tha... proliferate, all cells in the body need to produc... a process that requires oxygen. Compared with nor...
(Date:11/21/2008)...d To Vigorously Protect Investment And Restore Sha...ewswire-USNewswire/ -- Dr. Stephen Joffe, Craig Jo...heir Schedule 13D with the U.S. Securities and Exc...D disclosing ownership of 11.4% of LCA-Vision, Inc...ixed-site laser vision correction centers in 33 st...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7
...ith wins a court battle against United Health Euro...lthcare company and spoils their plan to run a GP ...for the tender to provide family doctors for the p...tinghamshire border. The North Eastern Derbyshire...
...abies being treated at the Royal Blackburn Hospita...n their skin, during routine tests.// Since then ...me the babies were being treated in the neonatal i...officials have said that none of these children be...
...r sudden infant death syndrome has been the cause ...to ensure the baby sleeps on its back. In a bid to... infant vulnerable, researchers discovered that in...ngs related genes were prone to the risk of SIDS. ...
...ed nuclear scientist Abdul Qader Khan, diagnosed w...nd the public would be kept informed of his health... health condition of Khan is of public interest, t...t best medical care was being provided to Khan in ...
Other Medicine News:Health News:Pensioner wins over a US healthcare giant 2Health News:Pakistan Assures of Providing Best Medical Care to Abdul Qader Khan 2
(Date:11/20/2008)... Calif., Nov. 20 Milk. It does a b...originally thought. After years of,research, scie...es found in,cow,s milk that stimulate the body,s ...ew the Multimedia News Release, go to:, http://www... While developing new cancer therapies, the chie...
(Date:11/20/2008)...Nov. 20 Clinical data from a prosp...nnual Veith Symposium shows DVT,treatment with th...us,Vascular, Inc. (Santa Clara, CA) successfully ...t 20 minutes. , This technique, called isol...ood flow more quickly and safely than current cath...
(Date:11/19/2008)...AKS, Calif., Nov. 19 Amg...ncology Company, a subsidiary of,Takeda Pharmaceu... that,enrollment in the Phase 3 MONET1 trial eval...clitaxel and carboplatin for the first-line treatm...) has been temporarily suspended,following a plan...
(Date:11/19/2008)...l., Nov. 19 Isogen, a contract dev...le filling, today announced the first,phase launc... founded to,specifically address the process, fac...ith the $2 billion highly-niched, low-volume clini...rket segment. , Companies can invest over $...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 1New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 2Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 1Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 2Chronic Stomach Inflammation Boosts Cancer Risk 20924 1Chronic Stomach Inflammation Boosts Cancer Risk 20924 2Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 1Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 2
...ieves All Key Endpoints for Both Efficacy and Safe...rstCall/ --,Indevus Pharmaceuticals, Inc. today an...inetic trial for NEBIDO (testosterone,undecanoate)...nder,development for the treatment of male hypogon...ng Pharma AG, Germany. The data,from the recently ...
... is evaluating zonisamide SR as a novel component ... June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(...ny focused on the,treatment of central nervous sys...day announced results from a Phase I trial evaluat...rietary,sustained-release (SR) formulation of zon...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)
Inquire
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
Medicine Products: